Insurance Hurdles Limit Injectable PrEP Access
Nearly half of St. Louis patients prescribed long-acting PrEP faced coverage barriers to receiving their injection.
Updated on Oct. 23, 2026 in Diabetes
Live Poll
Should insurance companies simplify their approval processes for preventative medical treatments?
A retrospective study at a St. Louis clinic found that 41.2 percent of patients failed to receive a prescribed long-acting injectable PrEP injection between February 2022 and March 2026. Administrative hurdles, specifically insurance coverage gaps and prior authorization denials, were the primary barriers to patient access.
Why it matters
Understanding these insurance obstacles highlights systemic barriers that prevent patients from accessing long-acting HIV prevention. For patients in the St. Louis area, these findings underscore the need to proactively communicate with providers and insurance plans to navigate potential coverage denials.
This retrospective cohort study of 170 patients at a St. Louis clinic evaluated access to long-acting injectable PrEP. Researchers found 41.2 percent of patients did not receive their prescribed injection, with pharmacy benefit gaps and prior authorization denials identified as the leading causes.
The players
UC Davis Health
An academic medical center that participated in surveying internal medicine residents on PrEP prescribing knowledge.
UChicago Medicine
An academic health system that contributed to the evaluation of medical resident education on long-acting injectable PrEP.
The details
Long-acting injectable PrEP requires consistent administration, but patients often face challenges due to insurance requirements. In this study, 54.3 percent of those who did not start treatment lacked necessary pharmacy benefits, while 41.4 percent faced prior authorization denials. These administrative gaps can delay necessary preventative care, as shown by one patient who experienced HIV seroconversion after coverage was denied.
Timeline
The study period for patients with at least one prescription ran from February 1, 2022 to July 7, 2026.
Researchers established a cutoff for the detailed patient analysis group in March 2026.
Research posters were presented at the IDWeek 2026 conference in October 2026.
Health Landscape
The study sits within the broader context of research presented at IDWeek 2026 concerning the clinical rollout of long-acting HIV prevention tools. It reflects a growing focus on the administrative and educational barriers that currently impede the broad clinical implementation of these therapies.
If you are prescribed long-acting injectable PrEP, it is worth discussing coverage and potential prior authorization requirements with your physician immediately. Confirming that your pharmacy benefits include this preventive medication can help you avoid delays in starting your treatment schedule.
The takeaway
Insurance denials and benefit gaps remain significant obstacles to accessing long-acting HIV prevention therapy. Patients should work closely with their care team to ensure coverage is verified well in advance of their scheduled appointment.
Further reading
Learn more about local health management at Diabetes.
Source note: This article includes information reported by Ajmc.
Live Poll
Should insurance companies simplify their approval processes for preventative medical treatments?
